Clinical trials: Liver Diseases, Alcoholic
Acute-On-Chronic Liver Failure
TAK-242 in Patients With Acute Alcoholic Hepatitis
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of…
- Trial name
- NCT04620148
- Testing
- TAK-242
- Where
- 3 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- Akaza Bioscience Ltd
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Non Alcoholic Steatohepatitis
the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.
This is a randomized, controlled study evaluating diosmin tablets administered daily for 3 months. The purpose of the study is to evaluate the efficacy and safety of diosmin on non-diabetic patients with non-alcoholic…
- Trial name
- NCT05942547
- Testing
- Diosmin
- Where
- Egypt
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tanta University
Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05766449
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
FibroScan-Reproducibility and Repeatability Study
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis.
- Trial name
- FibroScan-RR (NCT06877026)
- Testing
- FibroScan, Liver Enzymes
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Echosens
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Fasting, Non-alcoholic Fatty Liver Disease (NAFLD)
Regulation of FGF21 by Nutritional Challenges
The purpose of this study is to examine how acute nutritional challenges affect levels of several proteins involved in metabolism. These proteins will be measured in blood and fat tissue. This study will have several aims.
- Trial name
- NCT00968747
- Testing
- Fasting, Diet, oral carbohydrate challenge
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Impaired Glucose Tolerance, Pre-diabetes
Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth
The purpose of the study is to determine the role of beta-cell function and insulin resistance in the development of impaired glucose tolerance (IGT) and type 2 diabetes in children and adolescents who have an increased risk of…
- Conditions
- Impaired Glucose Tolerance, Pre-diabetes, Childhood Obesity, Insulin Resistance
- Trial name
- NCT00536250
- Where
- United States
- Volunteers
- 255 people, healthy volunteers welcome
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2.
- Trial name
- NCT00375349
- Testing
- Ultrasound to demonstrate existence of fatty liver
- Sponsor
- Shaare Zedek Medical Center
Non-Alcoholic Fatty Liver Disease
To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation
In this study, the improvement of the clinical status of early-stage non-alcoholic fatty liver disease (NAFLD) patients after the probiotic intervention will be assessed.
- Trial name
- NCT05402449
- Testing
- Probiotics
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GenMont Biotech Incorporation
HIV, Fatty Liver
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
People infected with HIV are living longer thanks to the use of antiretroviral therapy (cART). In aging HIV persons, other factors are associated with early death.
- Conditions
- HIV, Fatty Liver, Nonalcoholic Steatohepatitis
- Trial name
- NCT02210715
- Testing
- Isentress., Continue usual antiretroviral therapy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Non-alcoholic Fatty Liver Disease, Sleep Apnea, Obstructive
Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease
Obstructive sleep apnea (OSA) and nonalcoholic fatty liver disease (NAFLD) are frequently encountered in patients with metabolic syndrome (MS). Several data suggest that OSA per se could be a risk factor of liver injury.
- Trial name
- NASHSAS (NCT03373643)
- Testing
- OSA screening
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Fatty Liver Disease
Micro RNA Levels in NAFLD
Epidemiological study of NAFLD, NASH patients. Descriptions of altered miRNA profiles in NAFLD patients especially with fibrosis.
- Trial name
- NCT04574557
- Testing
- micro RNA
- Volunteers
- 80 people
- Sponsor
- Assiut University
Alcoholic Hepatitis
Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)
This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive…
- Trial name
- NCT05294744
- Testing
- N-acetylcysteine
- Where
- Spain
- Volunteers
- 390 people
- Sponsor
- Bioaraba Health Research Institute
Alcohol Related Disorders
Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics
The study objective was to determine whether liver injury develops in alcoholic patients who ingest therapeutic doses of APAP for three consecutive days.
- Trial name
- NCT00402571
- Testing
- acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Denver Health and Hospital Authority
Healthy
31P Magnetic Resonance Spectroscopy Fructose Study
The purpose of this study is to determine the effects of an oral fructose challenge on liver adenosine triphosphate (ATP) reserves using 31P magnetic resonance spectroscopy (MRS) as a potential measure measure of liver health.
- Trial name
- 31PMRS_FRU (NCT02217605)
- Testing
- Fructose
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stephen Bawden
NAFLD, Fatty Liver
Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome
Concurrent with the rising prevalence of childhood obesity, the co-morbid condition of non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease among children.
- Conditions
- NAFLD, Fatty Liver, Obesity, Metabolic Syndrome
- Trial name
- NAFLD (NCT02358928)
- Testing
- Diet Intervention
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass index and waist…
- Trial name
- NCT01759628
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences